China bladder cancer market is estimated to grow modestly at a CAGR of around 10.1% during the forecast period. The country has a strong healthcare industry and is continuously developing medical facilities and research centres to improve the industry further. Bladder cancer is one of the major cancers diagnosed in the elderly population of the country. The growing prevalence of bladder cancer in the country is attributed to growth in the aging population and a rapid increase in the number of smokers. Cancer is one of the leading causes of mortality in China. According to WHO, China has reported a total of 82,270 new cases of bladder cancer in 2018 out of which 38,208 cases resulted in mortality. As per the organization, China accounts for 222,292 bladder cancer patients in the last 5 years. Due to increasing industrialization in the country, harmful chemicals are being ejected into the atmosphere and chemical exposure is one of the major causes of bladder cancer. Therefore, with rapid industrialization in the country, China is estimated to contribute substantially to the global bladder cancer market during the forecast period.

Get Sample Copy of China Bladder Cancer Market at: https://www.omrglobal.com/request-sample/china-bladder-cancer-market

The companies which are contributing to the growth of China bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc.

China bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others.

For More Information, get A full report of China Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/china-bladder-cancer-market

Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Market Segmentation

China Bladder Cancer Market by Cancer Type

Transitional Cell Bladder Cancer/ Urothelial Carcinoma
Squamous Cell Bladder Cancer
Adenocarcinoma
Others (Sarcomas, Carcinoma in Situ)

China Bladder Cancer Market by Diagnosis

Cystoscopy
Biopsy
Urinalysis
Urine Cytology
Intravenous Pyelogram (IVP)
Others (Biomarkers)

China Bladder Cancer Market by Treatment

Surgery
Chemotherapy
Immunotherapy
Radiation Therapy
Others (Targeted Therapy)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/china-bladder-cancer-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404